
While there is no cure or prevention for Alzheimer’s, some treatments may help with the symptoms of this disease. But NeuroQuest has been working towards developing a screening tool for the at-risk population. Founded in 2008 in Misgav, Israel, NeuroQuest’s mission is to develop a simple blood test for the general population, ages 60 and older that is accurate and affordable and able to possibly replace PET scans.
With US headquarters in Charleston, SC, the science and intellectual property behind NeuroQuest comes from the Weizman Institute’s Technology Transfer Arm and from the acclaimed work of Prof. Michal Schwartz, Chair of Neuroimmunology at the Weizman Institute.
While testing for Alzheimer’s disease widely available and in use today, the tests do not allow for much time – the majority of patients tested are already suffering from the disease. But NeuroQuest’s science is hoping to be able to give patients and their families’ time to fight the disease and plan for the future.